Guido Mieth/DigitalVision via Getty Images
Investment Thesis
I last covered The Clorox Company (NYSE:CLX) in June last year. The stock has had quite a wild ride since then as the company’s sales and profit were impacted by a
Clorox: Attractively Valued With Good Prospects
Summary
- Clorox's revenue is expected to continue benefitting from inventory replenishment, increased advertising spend, and new product innovations.
- Clorox's margins are projected to expand and return to pre-pandemic levels, supported by moderating inflation and cost-saving initiatives.
- Valuation is lower than historical averages.
We focus on GARP (Growth at reasonable Price) opportunities in industrial, consumer, and technology sectors. We are among the top 50 financial experts (Out of ~39,000 tracked) as measured by Tipranks based on the consistency of our stock recommendations and returns generated https://www.tipranks.com/experts/bloggers/gs-analytics. Please click the "Follow" button to receive our latest research. If you have any questions, feel free to reach out to us through the comments section of our articles or SA messaging functionality.
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
This article is written by Gayatri S.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.